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Abstract
Purpose Bladder outflow obstruction (BOO) is common
in the elderly and can result in bladder voiding dysfunction
(BVD) due to severe bladder muscle damage. The goal of
this research was to evaluate the use of adult stem cells for
the treatment of BVD due to decreased muscle contractility
in a rat model.
Materials and methods Adipose-derived stem cells
(ADSCs) and muscle precursor cells (MPCs) were har-
vested from male Lewis rats and expanded in culture. BOO
was induced by tying a suture around the urethra. Six
weeks after obstruction, the development of BVD was
confirmed by cystometric analysis in conscious rats, his-
tology and molecular investigations. Injection of ADSCs or
MPCs into the bladder wall and synchronous deligation
was performed 6 weeks after the obstruction. After stem-
cell treatment, morphological and functional changes were
assessed. Age-matched rats and animals without cellular
therapy but deligation-only served as controls.
Results Voiding pressures decreased progressively
6 weeks after obstruction with increased bladder capaci-
ties. Structural changes of the detrusor muscle occurred
during the time of obstruction with an increased connective
tissue-to-smooth muscle ratio and decreased SMA/
smoothelin expression. After stem-cell injection, improved
voiding pressures and voiding volumes were observed
together with recovered tissue architecture. RT-PCR and
Western blotting showed an up-regulation of important
contractile proteins.
Conclusions We established a reliable model for BVD
and demonstrated that ADSCs and MPCs can prevent
pathophysiological remodelling and provide regenerated
bladder tissue and function.
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Introduction
Bladder outlet obstruction (BOO), such as benign prostatic
hyperplasia, is a common disorder affecting 50–80 % of
males over the age of 50 [1]. It causes various urinary
symptoms and leads to frequency, urgency and urgency
incontinence due to involuntary detrusor contractions in the
storage phase, and to hesitancy and weak flow in the
voiding phase with consequent urinary retention [2]. When
identified and treated early, the long-term sequel of BOO
can be avoided. However, if detected in the decompensated
stage, the voiding dysfunction often remains after surgical
treatment due to the loss of bladder smooth muscle [3].
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Currently, no treatment modality reverses the underlying
cause, which is the decreased bladder contractility. In most
cases, a long-term indwelling catheter is necessary,
entailing all its disadvantages.
Tissue engineering and cellular therapy offer novel
strategies to potentially revert the deterioration of muscle
tissue and improve bladder contractility. Most current
strategies for tissue engineering depend upon a sample of
autologous cells from the diseased organ of the patient.
However, biopsies from patients with extensive end-stage
organ failure and fibrosis of the bladder may not yield
enough normal cells. Therefore, we have used easily
accessible adult cells, namely adipose-derived stem cells
(ADSCs) and muscle precursor cells (MPCs) as an alter-
native source in this study.
ADSCs are well-suited for regenerative medicine
because of ease of harvest for autologous transplantation,
high proliferation rates for ex vivo expansion and multi-
lineage differentiation capacity [4]. We use the term MPCs
for the pool of precursor cells harvested from muscle tissue
expressing muscle-specific markers and giving rise to new
muscle tissue [5]. MPCs have previously demonstrated
long-term survival, the ability to form new myotubes [6],
the formation of new motor units [7] and differentiation to
smooth muscle cells [8]. The goal of this project is to
evaluate the use of autologous stem cells for the treatment
of bladder voiding dysfunction (BVD).
Materials and Methods
(Experimental procedures are in supplementary and avail-
able online).
Study design
For the generation of bladder hypocontractility, we used a
modified model of BOO [9, 10]. Morphological, histolog-
ical and functional data (cystometry) were collected
6 weeks after partial obstruction of the urethra. Cysto-
metric analysis was performed without anaesthesia after
implantation of a subcutaneously tunnelled catheter into
the bladder. Healthy age-matched animals served as normal
controls. All study animals had a partial urethral obstruc-
tion for 6 weeks followed by either deligation-only or de-
ligation with cell injection (ADSCs or MPCs) (Figure S1).
Animal model generation
All animal research was performed in accordance with the
Animal Ethics Committee and Animal Welfare Law.
Borgal 24 % (Sulfadoxin?Trimethoprim) and Buprenor-
phin (Temgesic, 2 ml Amp, 0.3 mg/ml, 0.1–0.2 mg/kg)
were administered prior to surgery. Under anaesthesia with
isoflurane 3 %, a 1 cm midline incision was made from the
penoscrotal junction to the midscrotum to gain access to
the bulbous urethra. The urethra was then isolated from the
cavernous bodies. A sterile metal bar with a diameter of
0.91 mm was placed on the bulbous urethra and a 3-0
polypropylene suture was tied around both the urethra and
the bar. The metal bar was then removed, leaving the
prostatic urethra partially obstructed. A 3-0 vicryl suture
was used for wound closure.
Results
We analysed data of 53 male Lewis rats (6–8 weeks old
weighing 225–300 g). In group one, 12 rats were evaluated
to confirm bladder hypocontractility. In group two, 12
animals received partial urethral obstruction and deligation
6 weeks later. In groups three and four, deligation and
stem-cell injection (12 animals with ADSCs and 12 ani-
mals with MPCs, respectively) into the bladder wall was
performed 6 weeks after the obstruction. Five healthy age-
matched rats served as normal controls. Animals with signs
of acute urinary retention or infection after obstruction
were terminated early and replaced.
Bladder hypocontractility 6 weeks after partial urethral
obstruction
Obstructed rats had a significantly larger bladder weight
(178.3 ± 20.9 mg vs. 57.6 ± 5.2 mg, p = 0.0011) and a
lower bladder wall thickness (434.7 ± 39.0 lm vs.
815.8 ± 177 lm, p = 0.0067) than normal controls
(Fig. 1). Histological examination showed an increased
connective tissue-to-smooth muscle ratio in the obstructed
bladder (0.6 ± 0.05 vs. 0.47 ± 0.12) compared with nor-
mal controls (Fig. 2). Functional analysis in the obstructed
bladder showed significantly lower maximum peak pres-
sure, threshold pressure as well as lower voiding volumes.
Furthermore, mean values of average slope/cm2 H2O was
significantly lower compared with the normal bladder
(Figs. 1 and 4).
Cellular therapy with ADSCs and MPCs
ADSCs with an overall purity of more than 65 % for CD44
and CD29 and low levels of CD34 (\5 %) were used for
this study. MPCs with a purity of more than 90 % for
MYHC and 60 % for Desmin and Actinin were injected
(Figure S2). After harvesting the bladder, there were no
signs of tumour formation, adhesions or inflammation.
Data collected 4 and 8 weeks after deligation and stem-
cell injection were likewise, therefore they were pooled
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and labelled ‘‘post-treatment’’. Stem-cell therapy improved
tissue architecture with increased smooth muscle clusters
(Fig. 2). PKH-labelled cells were tracked after 4 weeks and
found to be arranged in dense muscle clusters. Connective
tissue-to-smooth muscle ratio was lower in the ADSCs
group (0.36 ± 0.12) compared with the obstructed group
(0.6 ± 0.05), whereas it remained high in the deligation
group (0.67 ± 0.14). Similarly, the MPCs group revealed a
lower connective tissue-to-smooth muscle ratio than the
obstructed bladder (0.4 ± 0.06).
To assess the tissue of the bladder wall, immunostaining
of smooth muscle-associated proteins were performed
(Fig. 3). SMA was detected in muscle areas of all treated
samples with a lower expression in the animals with deli-
gation. These findings were confirmed by staining of
smoothelin, the key contractile protein with high levels of
expression in animals after stem-cell injection.
Functional assessment after cellular treatment
Cystometry studies demonstrated a higher maximum mic-
turition and threshold pressure after cell injection with
ADSCs and MPCs compared with the obstructed and the
deligated groups (Figs. 4 and 5). The maximum peak
pressure using ADSC (41.7 ± 8.4 cmH2O, n = 6) and
MPC (42.5 ± 0.1.8 cm H2O, n = 5) were both signifi-
cantly (p \ 0.05) higher than in the obstructed group
(16.6 ± 5.8 cmH2O, n = 6), showing improved function
similar to untreated normal control animals (45.9 ± 1.24
cmH2O, n = 5). Furthermore, an increased threshold
pressure was found after ADSCs (13.0 ± 4.3 cmH2O) and
MPCs (13.81 ± 2.2cmH2O) injections, whereas in the
deligation group (8.7 ± 2.9 cmH2O, n = 6), a lower
threshold pressure was noticed. A similar pattern of
improved average slope was observed after ADSCs and
MPCs treatments (0.7 ± 0.2 cmH2O and 1.8 ± 0.19
cmH2O, respectively) compared with the obstructed group
(0.42 ± 0.3 cmH2O). The ADSCs and MPCs groups
(0.82 ± 0.2 and 0.95 ± 0.2 ml, respectively) showed an
improved bladder voiding volume compared with group
one (0.55 ± 0.19 ml). Conversely, the deligation group
(0.5 ± 0.13 ml) did not reach the levels of the ADSCs- or
MPCs-treated groups.
Gene expression and Western blot (WB)
At mRNA level, an increased expression of calponin, MYH11
and smoothelin was observed in the stem-cell- treated groups
Fig. 1 Morphological and functional characterization of normal and
obstructed bladder 6 weeks after partial urethral obstruction. Bladder
weight (a), wall thickness (b), connective tissue-to-smooth muscle
ratio (c) and micturition pressure (d). Representative images of a
normal and obstructed bladder (e)
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compared with obstructed animals (Figure S3). WB analysis
revealed increased levels of smoothelin, calponin and MYH11
in the treated animals compared with the deligated animals.
Above all, smoothelin was higher expressed in the stem-cell-
treated groups than in the deligation groups, whereas only a
weak basal expression of calponin and MYH11 was found in
the deligation group.
Discussion
Cellular therapy using autologous cells improving bladder
function would certainly represent a major medical
breakthrough. The mechanism of bladder restoration can be
explained by a combination of cell differentiation, para-
crine factors from the stem cells and microenvironmental
signals [11]. Homing and recruitment of other haemato-
poietic or mesenchymal stem cells to sites of injury
chemoattracted through microenvironment niche condi-
tions have been suggested to accelerate bladder regenera-
tion [12]. Certain cues signal the stem cells to activate their
differentiation potential for the regeneration or repopula-
tion of a tissue [12] [13] [14]. In this study, we mimicked
this process by injecting autologous stem cells directly into
the damaged bladder tissue at multiple locations. Further-
more, we determined whether cell treatment could improve
the bladder architecture in rats with BOO through smooth
muscle restoration and regeneration. Thus, the present
study provides insights into the possible use of two adult
stem cell sources for bladder bioengineering.
In a recent study, autologous ADSCs were seeded
onto bladder acellular matrix grafts for bladder
Fig. 2 a Masson’s Trichrome
staining 4 and 8 weeks after cell
injection, with quantitative
analysis of connective tissue-to-
smooth muscle ratio.
b Representative images of
PKH 67-labelled (green) cells
arranged in dense clusters after
stem-cell injection
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reconstruction in a rabbit model [15]. ADSCs promoted
the regeneration of smooth muscle, neural tissue and
also the compound graft [15]. In addition, ADSCs were
found to improve urge [16] and stress urinary inconti-
nence in a rat model [17]. MPCs that are predecessors
of the satellite cells are considered not to be restricted
to the myogenic or mesenchymal tissues [18]. In a
recent study, muscle-derived multipotent stem cells
(CD34?/45- and CD34-/CD45-) from green fluorescent
protein transgenic mouse muscles were transplanted into
a nude rat model for regeneration of neurogenic bladder
dysfunction [19]. A significantly higher functional recovery
4 weeks after cell injection was found compared with the
controls. In another study, muscle-derived stem cells were
reported to possibly differentiate into bladder smooth muscle
cells [8] and demonstrated contractile activity after seeding
[20].
In our study, the induced obstructed bladder model
showed a significant decrease in bladder wall thickness
and maximum peak pressure but increased bladder weight
with larger bladder capacities compared with normal
bladder in control rats. In addition, structural changes of
the detrusor muscle occurring during obstruction resulted
in increased connective tissue-to-smooth muscle ratio and
decreased SMA and smoothelin expression. Although
BOO is a well-established procedure in rodents [21], the
use of this model to induce hypocontractility remains
challenging. In our hands, animals demonstrated a high
variety in pathophysiological changes after 6 weeks of
obstruction. This variability made it difficult to reach
statistical significance, although all trends were in favour
of cell treatment.
The functionality of regenerated smooth muscle bundles
in treated and control animals was further investigated by
cystometric analysis, which is the standard for functional
evaluation of the lower urinary tract [22]. Our observation
revealed significantly improved voiding pressures in the
stem-cell-treated groups. Interestingly, the control rats after
deligation, representing the transurethral resection of the
prostate in patients, also demonstrated a level of natural
healing capacities with partial recovery of contraction,
which is not seen in patients with hypocontractile bladders
in clinics.
We demonstrated that deligation and synchronous
stem-cell treatment prevented further pathophysiological
remodelling of the bladder wall, with histology showing
the regrowth of smooth muscle bundles within the
regenerated urinary bladder wall. Connective tissue-to-
smooth muscle ratio was reduced in ADSCs and MPCs-
treated groups compared with obstructed and deligated
groups. When compared to the untreated group, the
animals injected with either ADSCs or MPCs also
showed a trend of lower collagen-to-smooth muscle
ratio. The injected stem cells thus seem to have a sup-
portive effect on improved remodelling with fast muscle
regeneration.
In addition, we tracked the injected cells dispersed in
dense muscle clusters. The recovered tissue architecture
was confirmed by gene expression pattern and translation
of important contractile proteins in cell-treated bladder
tissue. Two major structural proteins in SMC, SMA and
smoothelin were used to verify the regeneration of
muscle tissue. SMA is an early and general marker of
developing smooth muscle, but its expression is not
Fig. 3 Representative immunohistochemical staining of the different
groups. Tissue sections were immunostained for smooth muscle
markers SMA and smoothelin. Proteins were detected using CY3-
conjugated secondary antibody (red) and DAPI (blue). Red colour
indicates expression of each protein and blue colour indicates the
nucleus. Scale bar = 100 lm
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restricted to smooth muscle. Smoothelin is a marker of
the differentiated phenotype, and its expression is
restricted to functional smooth muscle [23]. Deligated
bladders treated with ADSCs and MPCs showed high
levels of both SMA and smoothelin expression. This
finding suggests that either paracrine factors from
injected ADSCs and MPCs support smooth muscle
regeneration or the injected cells formed new smooth
muscle tissue [24]. As reported, the interaction of cell
surface receptors, ligands and short-range-acting mole-
cules between differentiated and undifferentiated cells
significantly contribute to stem-cell differentiation [25].
Fig. 4 Overview of the cystometric analysis with maximum peak pressure (a), threshold pressure (b), average slope (c) and voiding volume (d).
e Summary tables of cystometric analysis with maximum peak pressure and average slope
1246 World J Urol (2014) 32:1241–1248
123
Conclusion
We established a reliable small animal model for hypo-
contractile bladder and demonstrated that ADSCs and
MPCs support the early restoration of BVD. Our results
show improved voiding pressures and molecular expres-
sion of contractile proteins after cell therapy.
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